Advanced search
Publication Cover
Expert Opinion on Therapeutic Patents Volume 13, 2003 - Issue 2
Submit an article Journal homepage
78
Views
2
CrossRef citations to date
0
Altmetric
Miscellaneous

The many lives of itraconazole

Richard Hector UCSF Prevention Sciences Group, 74 New Montgomery Street, Suite 508, San Francisco, CA 94105, USA. [email protected]
Pages 141-148 | Published online: 02 Mar 2005

Bibliography

  • MARICHAL P, GORRENS J, VANDEN BOSSCHE H: The action of itraconazole and ketoconazole on growth and sterol synthesis in Aspergillus fumigatus and Aspergillus Inger Sabouraudia (1985) 23(1):13–21.
  • ••Early publication describing the impressivepotency of itraconazole in vitro.
  • VAN CUTSEM J, VAN GERVEN F, VAN DE VEN MA, BORGERS M, JANSSEN PA: Itraconazole, a new triazole that is orally active in aspergillosis. Antlinicrob. Agents Cheinother. (1984) 26(4):527–534.
  • DEL PALACIO HERNANZ A, FRIAS-INIESTA J, GONZALEZ-VALLE O, BORGERS M, VAN CUTSEM J, CAUWENBERGH G: Itraconazole therapy in pityriasis versicolor. Br. J. Dermatal (1986) 115(2):217–225.
  • ••Early publication describing one of the first human trials with itraconazole.
  • WALSH TJ: Management of immunocompromised patients with evidence of an invasive mycosis. Heinatal. Oncol. Clin. North Am. (1993) 7(5):1003–1026.
  • DUCHINI A, REDFIELD DC, MCHUTCHISONJG, BRUNSON ME, POCKROS PJ: Aspergillosis in liver transplant recipients: successful treatment and improved survival using a multistep approach South Med. J. (2002) 95(8):897–899.
  • •Recent article describing current management practices of patients at risk for life-threatening Aspergillus infections.
  • OSCHERWITZ SL, RINALDI MG: Disseminated sporotrichosis in a patient infected with human immunodeficiency virus. Clin. Infect. Dis. (1992) 15(3):568–569.
  • TAN TQ, OGDEN AK, TILLMAN J, DEMMLER GJ, RINALDI MG. Paecaomyces blacinus catheter-related fungemia in an immunocompromised pediatric patient. Clin. Microbial. (1992) 30(9):2479–2483.
  • EDMOND MB, WALLACE SE, MCCLISH DK, PFALLER MA, JONES RN, WENZEL RP: Nosocomial bloodstream infections in United States hospitals: a three-year analysis. Clin. Infect. Dis. (1999) 29(2):239–244.
  • •Good review of the types and numbers of serious fungal infections seen in the US.
  • REX JH, WALSH TJ, SOBEL JD et al.: Clinical guidelines from the infectious diseases society of America. Practice guidelines for the treatment of Candidiasis. Infectious Diseases (2000) 30:662–678.
  • •Good review of current clinical approaches to the treatment of candidiasis.
  • HEYKANTS J, VAN PEER A, VAN DE VELDE V et al.:The clinical pharmacokinetics of itraconazole: an overview. Mycoses (1989) 32\(Supp1.1):67–87.
  • HARDIN TC, GRAYBILL JR, FETCHICK R, WOESTENBORGHS R, RINALDI MG, KUHN JG: Pharmacokinetics of itraconazole following oral administration to normal volunteers Antimicrob. Agents Chemother. (1988) 32(9) :1310–1313.
  • •Early paper describing the poor pharmacokinetic properties of itraconazole.
  • VANDEN BOSSCHE H, DROMER F, IMPROVISI I, LOZANO-CHIU M, REX JH, SANGLARD D: Antifungal drug resistance in pathogenic fungi. Med. Mycol (1998) 36\(Supp1.1):119–128.
  • REYNES J, BAZIN C, AJANA F et al.: Pharmacokinetics of itraconazole (oral solution) in two groups of human immunodeficiency virus-infected adults with oral candidiasis. Antimicrob. Agents Chemother. (1997) 41(11):2554–2558.
  • ••Paper describing the dramatic improvements in the pharmacokinetics of itraconazole solution.
  • LANGE D, PAVAO JH, WU J, KLAUSNER M: Effect of a cola beverage on the bioavailability of itraconazole in the presence of H2 blockers. Clin. Pharmacol (1997) 37(6):533–540.
  • KOKS C, MEENHORST P, BULT A, BEIJNEN J: Itraconazole solution: summary of pharmacokinetic features and review of activity in the treatment of fluconazole-resistant oral candidosis in HIV-infected persons. Pharmacol Res. (2002) 46(2):195.
  • ••Paper describing the dramatic improvements in the pharmacokinetics of itraconazole solution.
  • GROLL AH, WOOD L, RODEN M et al: Safety, pharmacokinetics, and pharmacodynamics of cyclodextrin itraconazole in pediatric patients with oropharyngeal candidiasis. Antimicrob. Agents Chemother. (2002) 46(8):2554–2563.
  • ••Paper describing the dramatic improvements in the pharmacokinetics of itraconazole solution.
  • RADHA TG, VISWANATHAN R: Allergic bronchopulmonary aspergillosis. Respiration (1978) 36(2):104–111.
  • DENNING DW, VAN WYE JE, LEWISTON NJ, STEVENS DA: Adjunctive therapy of allergic bronchopulmonary aspergillosis with itraconazole. Chest (1991) 100(3):813–819.
  • SKOV M, HOIBY N, KOCH C: Itraconazole treatment of allergic bronchopulmonary aspergillosis in patients with cystic fibrosis. Allergy(2002) 57(8):723–728.
  • HURLIMANN A, FAH J: Asthma, rhinitis and dermatitis triggered by fungal infection: therapeutic effects of terbinafine. Dermatology (2001) 202(4):330–332.
  • PEREA S, GONZALEZ G, FOTHERGILL AW, SUTTON DA, RINALDI MG: In vitro activities of terbinafine in combination with fluconazole, itraconazole, voriconazole, and posaconazole against clinical isolates of Candida glabrata with decreased susceptibility to azoles. .1. Clin. Microbiol (2002) 40(5):1831–1833.
  • RUBIN MA, CARROLL KC, CAHILL BC: Caspofungin in combination with itraconazole for the treatment of invasive aspergillosis in humans. Clin. Infect. Dis. (2002) 34(8):1160–1161.
  • •A recent example of clinical empirical combinations of antifungal agents.
  • LECHA M: Amorolfine and itraconazole combination for severe toenail onychomycosis; results of an open randomized trial in Spain. Br. J. Dermatol (2001) 145\(Supp1.60):21–26.
  • CHILLER TM, STEVENS DA: Treatment strategies for Aspergillus infections. Drug Resist. Update (2000) 3(2):89–97.
  • LI RK, RINALDI MG: In vitro antifungal activity of nikkomycin Z in combination with fluconazole or itraconazole. Antimicrob. Agents Chemother. (1999) 43(6):1401–1405.
  • GEORGOPAPADAKOU NF: Update on antifungals targeted to the cell wall: focus on P-1,3-glucan synthase inhibitors. Expert Opin. Investig. Drugs (2001) 10:269–280.
  • •Good review on antifungals and the 13-glucan inhibitors.
  • KONTOYIANNIS DP, LEWIS RE, MAYS GS, ALBERT ND, RAAD II: Sequential exposure of A. fumigatus to itraconazole and Caspofungin; evidence of enhanced in vitroactivity of this combination. Abs. 42nd Intersci. Conf. Antimicrob. Agents Chemother. (2002) Abstract M–851.
  • MANAVATHU EK, ALANGADEN GJ, CHANDRASEKAR PH: Differential activity of triazoles in 2-drug combination with the echinocandin Caspofungin against Aspergillus fumigatus. Abs. 42nd Intersci. Con]: Antimicrob. Agents Chemother. (2002) Abstract M–854.

Websites

  • http://www.fda.gov/cder/drug/advisery/ sporanox-lamisil/advisery.htm)

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.